The European Commission approved the first biosimilar, generic equivalent, of Remicade yesterday. Remicade is an infusion used for many inflammatory conditions such as rheumatoid arthritis and Chron’s disease. Specialty medications are very complex medications and unlike other medications are very difficult to manufacture. The Wall Street Journal announcement is provided below with additional information and for your reference. We will have to wait and see how and when the FDA will address biosimilars here in the US as they work towards final language of the biosimilar legislation.
Click here for related article in Rueters.com.
To download a copy of this article for your reference, or to share with others, click here.